XenoPort (XNPT) Misses Q2 EPS by 7c

XenoPort (NASDAQ: XNPT) reported Q2 EPS of ($0.39), $0.07 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $9.77 million.

Ronald W. Barrett, Ph.D., chief executive officer of XenoPort, stated, “In the second quarter, we saw strong growth of HORIZANT prescriptions and net sales. With the recent addition of approximately 50 new Neuroscience Health Specialists to educate a broader pool of healthcare providers about HORIZANT, we believe that there will be an acceleration of growth in HORIZANT sales in the second half of the year and that we are on track to meet our net sales guidance of $39 to $43 million for 2015. We are excited that the NIAAA has initiated its AUD study of HORIZANT. This large study of approximately 350 subjects will provide important information about HORIZANT as a potential treatment for patients with AUD.”

Dr. Barrett continued, “Our XP23829 Phase 2 clinical trial in patients with moderate-to-severe chronic plaque-type psoriasis is nearing completion and, as previously indicated, we look forward to reporting the top-line results by the end of the third quarter. We believe this trial has the potential to be the first demonstration of efficacy of a monomethyl fumarate prodrug other than dimethyl fumarate and that XP23829 could provide a differentiated profile with potential for once-a-day dosing, reduced flushing and/or better GI tolerability.”

For earnings history and earnings-related data on XenoPort (XNPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Movano (MOVE) Misses Q2 EPS by 195c